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8 In N-glycosylation analysis of biopharmaceuticals, analytical need depends on the phase of the manufacturing process. All
9 important glycoanalysis steps are thoroughly discussed. Carbohydrate sequencing by exoglycosidase arrays isomers is described
10 in conjunction with capillary electrophoresis (CE) to identify linkage and positional. A possible automated workflow for glyco-
11 analysis based on CE is outlined.
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atrix-assisted laser desorption/ionization mass spectrometry; Man, Mann
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1. Introduction
This article reviews the app
capillary electrophoresis (
associated techniques for com
N-glycosylation analysis of bi
tics. Progress in the field has
because the formation of glyc
template driven, resulting in h
thousands of possible struc
specificity and microheterogen
their characterization even m
lenging. With respect to fulfil
regulatory agency requireme
considered to be a purely
method to liquid chromatogr
and mass spectrometry (MS), th
an important addition to the e
analytical toolsets.
With the rapidly growi
biotherapeutics market [1],
high-resolution bioanalytical
are required for the comprehe
acterization of biotherapeutics
analysis of post-translational
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luding
difica-
tions (PTMs), higher order structures and
protein aggregation, which are all impor-
tant in understanding their behavior [2]
(e.g., changes in PTMs may influence
higher order structure formation, leading
to possible malfunctioning of the biother-
apeutic agent). One of the most prevalent
PTMs is the carbohydrate moiety attached
to the protein, which is closely monitored
during the manufacturing process (i.e.
clone selection, product development and
lot release). Glycosylation is a highly
dynamic PTM [3] and one can even
extend the well-known central dogma
with the glycosylation modification step as
DNAﬁ RNAﬁ Polypeptideﬁ Glycopro-
tein. Glycans protect proteins, orient
binding faces, prevent non-specific inter-
actions and increase protein stability, just
to mention some of their most important
roles (e.g., N-glycan shield large areas of
protein surfaces from proteases).
Protein-glycosylation analysis, a sub-set
of analytical glycobiology, provides infor-
mation about the glycan structures that0.1016/j.trac.2013.04.006 1
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15 May 2013given cell types or organisms attach to biopharmaceu
ticals during production. The two major glycosylation
types occur in biotherapeutics are N-linked and O-linke
carbohydrates (see examples in Fig. 1). N-linked glycan
are attached to the protein backbone through a well
defined consensus sequence of Asn-X-Ser/Thr (where X
can be any amino acid except proline) through the side
chain amine group of the asparagine residue [4]. First,
14-sugar precursor is co-translationally added to th
asparagine in the polypeptide chain of the target protein
Figure 1. Main glycosylation types on biotherapeutics. Upper left
linked structures. The symbolic representation of glycan structuresThe structure of this precursor is common to most
eukaryotes, and contains 3 glucose, 9 mannose, and 2
N-acetylglucosamine residues [3]. A complex set of
reactions attaches this branched structure to a carrier
molecule (dolichol), which is then transferred to the
appropriate point on the polypeptide chain as it is
translocated into the ER lumen and processed post-
translationally. O-glycans on the other hand are bound
through the side-chain OH group of serine or threonine
residues with no consensus sequence requirement, and
have at least 8 different core types [3].
Protein glycosylation involves the interplay of several
hundred enzymes, and mutations in glycosylation pro-
cessing enzymes can significantly alter the resulting su-
gar structures. In addition, glycosylation is specific to
cells, proteins and sites, responsive to cell-culture con-
ditions and may be modulated by bioprocessing condi-
tions. As such, alterations in the process may even result
in the incorporation of immunogenic epitopes (e.g.,
galactose-a-1,3-galactose (a-1,3-Gal) and N-glycolyl-
neuraminic acid (NGNA) [5]} {e.g., Chinese hamster
ovary (CHO) cells, a commonly used host cell line in the
production of biotherapeutics, can synthesize galactose-
2 http://www.elsevier.com/locate/trac
Please cite this article in press as: A. Guttman, Trends Anal. Chem. (20a-1,3-galactose epitopes, as recent studies revealed [6]}
Therefore, in addition to the thorough glycosylation
profile analysis during the production of biotherapeutics
identification of potentially immunogenic epitopes is als
very important and strongly advised by regulator
agencies [7,8].
2. Glycosylation-analysis options
nked complex; Upper right: N-linked high mannose; Lower panel: O-
adapted from [54].112Various tools are available for the analysis of carbohy-
113drates. One of the most important is NMR [9], but the
114amount of material this method requires is often in the
115high-lg range [10]. Lectins, specific for particular
116glycosylation structures, are also widely used, often in
117an array format with or without antibodies (Abs) [11].
118An important development was the introduction of
119hydrophilic interaction LC (HILIC) of fluorophore-labeled
120glycans [12]. This method, when in conjunction with
121exoglycosidase-array digestion, has been automated
122using a microtiter-plate-based system for analysis at a
123low level of detection [13]. MS is also a widely used
124technique in carbohydrate analysis [14], but, while
125powerful, it may not be quantitative [15]. In one
126approach, the released glycans are permethylated in
127strong base solution or using a sodium hydroxide
128microcolumn [16]. The permethylated derivatives have
129sufficiently different hydrophobicities to accommodate
130their separation by reversed-phase LC (RPLC), followed
131by matrix-assisted laser desorption/ionization MS
132(MALDI-MS) [17], or electrospray ionization MS (ESI-
133MS) [18]. ESI-MS is applied directly or after LC separa-
134tion on porous graphitized carbon columns [19] or HILIC
13), http://dx.doi.org/10.1016/j.trac.2013.04.006
135 columns [20]. Albeit, this method can be sensitive,
136 interpretation of MS/MS spectra may be difficult, and
137 recovery from the porous graphitized carbon stationary
138 phase maybe problematic, especially for highly sialylated
139 structures [21]. Please note that the single-stage MS
140 mode only reveals glycan composition (i.e. the number
141 of Hex, HexNAc, and Neu5Ac), and gives no information
142 on linkages and positions. However, the MS/MS mode
143 can utilize fragmentation types (e.g., CID, ETD, and
144 photodissociation) to provide some linkage and posi-
145 tional information. But, please note that labile residues
146 can break off during the ionization process leading to
147 false information that can be misleading during the
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Pvelopment of the biopharmaceutical-manufacturing
ocess.
Close attention should be paid to sialic acid and core
cosylation residues, which are especially sensitive
ring ESI-MS analysis. Loss of such residues of up to
0% was reported during ESI-MS analysis in comparison
liquid-phase analytical methods (e.g., HPLC) [22].lycan structures can also be somewhat assessed by LC/
I-MS analysis of glycopeptides [23]. Another high-
rformance bioanalytical method for glycan analysis is
E with laser-induced fluorescent (LIF) detection [24].
E-LIF can readily distinguish both linkage and posi-
onal isomers, so it became widely used for glycan
alysis in the biomedical and biotechnology fields [25],
pecially in conjunction with the exoglycosidase-
gestion array [26].
CE can be coupled to MS for the analysis of carbohy-
ates and glycopeptides for glycoform profiling of bio-
erapeutics [5,27,28]. Another advantage of CE-based
stems is the option of easy multiplexing even up to 48
br
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Figure 2. Comparative separation of APTS-labeled Glc(a1 ﬁ 4)n and Glc(b1 ﬁ
linear (Glcb1 ﬁ 4 linkage) shapes of the respective sugar oligomers.
lease cite this article in press as: A. Guttman, Trends Anal. Chem. (2013),96 capillaries for high-throughput applications
9,30].r decades, CE has been extensively used for the anal-
is of fluorophore-labeled oligosaccharides in free solu-
on [31], or gel-filled columns [32]. In both cases, the
paration of the labeled sugar structures is based on
fferences in their hydrodynamic volume-to-charge
tio. In gel-filled capillaries, some interaction of the
alyte molecules with the sieving matrix cannot be
led out, as was suggested earlier [33]. To obtain CE
igration-time data with high precision (<0.05% RSD),
-injection of a lower bracketing standard (migrating
ster than any structures in the sample mixture) and a
igher bracketing standard (migrating slower than any
ructures in the sample mixture) is highly recom-
ended. Once the migration times are normalized by the185acketing standards, the corresponding glucose-unit
186U) values can be calculated using Equation (1) and
187sed for database search for possible matching structures
1884]:
189
Ux ¼ Gn þ MT
0
x MTn
MTnþ1 MTn ð1Þ 191
192here GUx is the GU of the unknown glycan; Gn is the
193gree of polymerization of the preceding homooligomer;
194T 0x is the corrected migration time of the unknown
195ycan; MTn is the migration time of the preceding
196omooligomer; and, MTn+1 is the migration time of the
197bsequent homooligomer.
4)n ladders. The insets show the helical (Glca1 ﬁ 4 linkage) and
http://www.elsevier.com/locate/trac 3
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198 d
199 e
200 s
201 e
202 ,
203 e
204 t
205e
206
207n
208
209
210-
211s
212with the release of sugar moieties from the biopharma-
213ceutical products (both innovative and biosimilars)
214s
215-
216e
217-
218-
219
220
221
222
Trends Trends in Analytical Chemistry, Vol. xxx, No. x, 2013
TRAC 14075 No. of Pages 10
15 May 2013Fig. 2 compares the separation of a Glc(a1ﬁ 4)n an
a Glc(b1ﬁ 4)n ladder, which both comprise glucos
elements but with a and b linkages, respectively. Thi
linkage difference caused significant migration-tim
shifts due to their shape differences. As the inset shows
the Glc(a1ﬁ 4)n ladder is helical, while th
Glc(b1ﬁ 4)n ladder is linear, rendering differen
Table 1. Calculated glucose unit values of Glc(b1 ﬁ 4)n homoo-
ligomers (second column) based on the degree of polymerization
of Glc(a1 ﬁ 4)n oligomers (first column)
Glucose unit
DP Glc(b1ﬁ 4)
1 1.000
2 1.810
3 2.488
4 3.523
5 4.832
6 6.342Figure 3. Main sample-preparation steps for capillary electrophoresis an
partitioning by ethanol precipitation; and, (C) APTS labeling.
4 http://www.elsevier.com/locate/trac
Please cite this article in press as: A. Guttman, Trends Anal. Chem. (20hydrodynamic volumes for sugar chains with the sam
degree of polymerization (DP). Numerical representation
of the corresponding GU values for the Glc(b1ﬁ 4)
oligomers is shown in Table 1.
4. Sample-preparation issues
The main sample-preparation steps for CE analysis of N
linked glycans are shown in Fig. 3. The process start(Fig. 3A), followed by partitioning the released sugar
[e.g., by ethanol precipitation of the remaining poly
peptide chain (Fig. 3B)] and fluorophore labeling of th
partitioned sugars (Fig. 3C). Glycan release usually uti
lizes an endoglycosydase peptide N4-(N-acetyl-b-glucos
aminyl)asparagine amidase (PNGase-F).
Using the correct pH for the PNGase-F release reaction
(pH 7.0) is very important. If the pH of the reaction
buffer is too high or too low, it can cause epimerizationalysis of N-linked glycans. (A) Glycan release by PNGase F; (B) sugar
13), http://dx.doi.org/10.1016/j.trac.2013.04.006
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Ploss of sialic acids, respectively, which can change the
sulting glycosylation pattern [35].
The preferred enzymatic deglycosylation time at 37C,
12–16 h. This enzymatic reaction can be accelerated
as fast as 1–2 h at 50C; however, one should con-
der the possible loss of labile residues (e.g., sialic acids)
that temperature (50C), again resulting in a change
glycosylation pattern.
Other options to speed up glycan release are micro-
ave-assisted deglycosylation, immobilized PNGase F
zyme reactors, or pressure-cycling technology, as
scussed in [36]. These methods can decrease the re-
ase time to as short as just a couple of minutes or even
conds. Please note that other endoglycosidases (e.g.,
doglycosidase H and PNGase A) can also be employed
r N-glycan release, if necessary.
Once the carbohydrate structures are released form
e therapeutic glycoprotein, the next sample-prepara-
on step is their labeling by a charged fluorophore. Al-
ough a variety of different labeling agents have been
ggested in the past [37,38], for the time being, 8-
inopyrene-1,3,6-trisulphonic acid (APTS) [39] is used
e most. APTS labeling is a simple reductive amination-
sed reaction using a weak-acid catalyst (e.g., acetic
id or citric acid), and sodium cyanoborohydrate as
ducing agent in organic medium. The lower the pK of
e catalyst, the shorter is the reaction time, but, again,
rong acidity may raise stability issues for labile sugar
281su
282fil
283st
284th
285ti
286th
287insidues. The main advantages of reductive amination-
sed carbohydrate labeling are that the fluorophore
ly reacts with the reducing ends of sugars in a simple
e-step reaction with good derivatization yield (>90%)
d negligible structural selectivity [39]. Since only one
orophore is attached to each glycan structure, the
sulting labeled sugars are readily quantified with high
in
u
Table 2. Exoglycosidase-enzyme array-based carbohydrate sequencing. The l
the matrix. {Published with permission from [41]}
Enzymes/vials 1
Neuraminidase (NANase) x
b-Galactosidasa (GALase) -
b-N-Acetylhexosaminidase (HEXase) -
a-Mannosidase (MANase) -
a-Fucosidase (FUCase) -
lease cite this article in press as: A. Guttman, Trends Anal. Chem. (2013),nsitivity using detection by LIF or light-emitting diode
ED). Fluorescent labeling is accomplished with a large
cess of the labeling reagent, so removal of the
nconjugated dye is important, especially when elec-
okinetic injection is the way to introduce the sample
to the separation capillary, as this method causes
ased sample entry favoring the labeling reagent. The
ost common way to remove the excess derivatization
e is by Sephadex G10 resin or normal-phase/HILIC
ads [40].
. Carbohydrate sequencing
ll structural elucidation of glycans, including infor-
ation about the linkage and the position of the indi-
dual sugar residues, is accomplished by carbohydrate
quencing in a step-wise or array manner using specific
oglycosydase enzymes with appropriate sugar and
kage specificity, as shown in Table 2 [41]. In practice,
e fluorophore-labeled sugar structures are subject to
p-down digestion and bottom-up identification. This
eans that first one type of sugar residue (e.g., sialic
id, fucose, and GlcNAc) is removed from the non-
ducing end of the carbohydrate and the resulting
uncated structure is analyzed by CE-LIF. Then, the next
gar-residue types are removed and the resulting pro-
es analyzed again by CE-LIF, until the N-lined core
ructure of GlcNAc2Man3 is obtained. At this stage, all
e CE traces are compared and, based on the migration-
me shift and time changes of the individual peaks in all
e traces, the entire structure can be reconstructed
cluding the position and linkage information of the288dividual sugar-building blocks. The most frequently
289sed exoglycosidase enzymes are linkage-specific sialid-
ower panel depicts the cleavage spots of the individual enzymes in
2 3 4 5
x x x x
x x x x
- x x x
- - x x
- - - x
http://www.elsevier.com/locate/trac 5
http://dx.doi.org/10.1016/j.trac.2013.04.006
290 ases, galacosidases, fucosidases, hexosaminidases and
291 mannosidases [29,41]. It is important to note that
292 sialylated structures have higher charge states due to the
293 number of sialic-acid residues in addition to the three
294 negative charges of the APTS label. These extra charges
295 cause faster electrophoretic migration of these species,
296 resulting in possible comigration of multiple structures at
297 the early migration-time regime of the electrophero-
298 gram, making structural elucidation extremely chal-
299 lenging and sometimes even impossible.
300 To alleviate this problem, one can apply preparative
301 weak anion exchange (WAX) chromatography frac-
302 tionation of the sialylated glycans with the different
303 charge states before the derivatization reaction with the
304 charged fluorophore. This step separates sialo structures
305 (e.g., mono-, di-, tri-, and tetra-) and the fractions are
306 then handled as individual glycan pools (i.e. subject to
307 derivatization, purification and exoglycosidase-array-
308 y
309 -
310
311 -
312 -
313 r
314 -
315
316
317
318 -
319 t
320characterization and validation, as shown in Fig. 4.
321During all of these steps, careful analysis of the protein
322and its PTMs (e.g., glycosylation) are crucial. The first
323stage of this process is clone selection for glycoprotein
324therapeutics, which requires high throughput that
325usually involves screening hundreds of clones, including
326analysis of their glycosylation profile. Understanding the
327sugar-to-function relationship is already critical during
328the selection of cell lines to assure that it will provide
329appropriate PTMs for the required function (Quality by
330Design, QBD). Glycosylation analysis should also be ap-
331plied in all the following steps of biotherapeutic pro-
332duction; however, the number of samples but the speed
333of analysis is not then one of the most important factors.
334Finally, checking for appropriate glycosylation during lot
335release is the final, crucial glycoanalysis step.
336Many factors contribute to alterations in glycan pro-
337cessing on recombinant glycoproteins, including the
338t
339-
340a
341components), loss of cellular organelle organization (e.g.,
342,
343s
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352e
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15 May 2013based glycan sequencing). This method was successfull
applied to the analysis of heavily-sialylated biopharma
ceuticals (e.g., erythropoietin) [42]. Extra charges on
glycans can be caused by other groups (e.g., phosphor
ylation), in which case immobilized metal affinity chro
matography (IMAC) was successfully utilized for thei
partitioning before the application of the exoglycosidase
based sequencing [43].
6. Glycan analysis during biopharmaceutical
development and production
Manufacturing of biotherapeutics includes cloning, pro
tein expression, protein production, purification, produc
Figure 4. The manufacturing process of recombinant the6 http://www.elsevier.com/locate/trac
Please cite this article in press as: A. Guttman, Trends Anal. Chem. (20expression levels of the processing enzymes in the hos
cell line, monosaccharide nucleotide donor levels, cell
signaling pathways (cytokines/hormones, drugs, medidue to pH changes), mutations in genes, gene silencing
overexpression, bioprocessing environment such a
temperature, and oxygen level – just to list the importan
ones. Having the proper analytical toolset is therefor
absolutely necessary to ensure that the product possesse
correct glycosylation for the expected biomedical activ
ity. Having the proper glycoanalytical toolsets is o
contemporary importance, as, in a couple of years
dozens of biotherapeutic drugs will be off patent, s
companies will start producing their biosimilar version
[44]. Biosimilars are presumably produced in a sam
tic proteins where each step requires glycosylation analysis.13), http://dx.doi.org/10.1016/j.trac.2013.04.006
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Figure 5. Exoglycosidase digestion based a-1,3-Gal content analysis of an NCI reference standard monoclonal antibody. {Published with per-
mission from [50]}.
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Pay as the innovator products, but usually without ex-
t knowledge of the expression system and production
rameters of manufacturing of the innovator product.
hus, the glycosylation pattern of a biosimilar can be
ry different, changing some of the features in com-
rison to the innovative compound. Of course, it can
so result in a so-called bio-better product, but, by all
eans, the glycosylation pattern should be carefully
alyzed and documented.
The majority of current biopharmaceuticals (and bio-
395an
396im
397ti
398at
399im
400ad
401m
402pr
403
404ta
405im
406h
407sy
4081
409from the National Cancer Institute (NCI) [50]. Consec-
410u
411be
412ep
413th
414ar
415gl
416gal-containing glycan structures in this particular ref-
417er
418
419at
420tw
421te
422O
423Nmilars) are Ab therapeutics, in particular mAbs of the
G1 sub-type. IgG1 possesses approximately 2–3%
rbohydrate by mass, primarily attached to the highly-
nserved N-glycosylation site at ASP 297 in the CH2
main of the Fc region of each heavy chain [45]. Gly-
sylation variability on Ab therapeutics depends on the
ll line and expression conditions used, possibly leading
structural diversity with respect to their fucose, gal-
tose, sialic acid and N-acetylglucosamine content,
fluencing its biological activity, physicochemical
operties and last but not least the ADCC and CDC
nctions [46]. ADCC activity, if that is the mode of ac-
on of the Ab drug, can be enhanced by decreasing the
ount of core fucosylated glycans at ASP 297. N-ace-
lglucosamine and mannose residues at the same site
ovide ligands for Mannose Binding Protein. The pres-
ce of sialic acids somewhat suppresses ADCC and
ovides anti-inflammatory features, while galactosyla-
on enhances CDC function.
Besides the QBD considerations, other important as-
cts of glycomic analysis are the determination of the
esence or the absence of potential immunogenic epi-
pes, even at trace levels. a1,3-gal and NGNA moieties
e antigenic, so their level should be very carefully
ecked throughout the entire manufacturing process.
Please note that additional glycosylation sites may be
und in the hypervariable regions of the Fab portion oflease cite this article in press as: A. Guttman, Trends Anal. Chem. (2013),b therapeutics and should be analyzed accordingly
7].
. Detection of potentially-immunogenic epitopes
has been well documented that non-human oligosac-
aride motifs of galactose-a-1,3-galactose (a-1,3-Gal)
d N-glycolylneuraminic acid (Neu5Gc) may trigger
munogenic response in humans [48]. As glycosyla-
on is subject to cell-culture type and conditions, alter-
ions in the process can result in different levels of
munogenic sugars [49], and, since these epitopes may
versely affect the safety of biotherapeutic products,
inimizing their levels during product development and
oduction is very important.
Galactose-a-1,3-galactose residues usually get at-
ched to the non-reducing end of glycans. The high
munogenicity of a-1,3-gal is evidenced by 1% of all
uman Abs being against this epitope. Fig. 5 depicts a
stematic exoglycosidase-array-based approach to a-
,3-gal residue analysis of a reference standard mAbtive exoglycosidase-digestion steps, including alpha and
ta galactosidases, revealed the presence of a-1,3-gal
itopes on the 1-6 arm (left flowchart, structure 12), on
e 1-3 arm (right flowchart, structure 29) and in both
ms (structure 31) of the antennary structures of mAb
ycans. A quantitative study showed almost 10% a-1,3-ence material.
N-acetylneuraminic acid (Neu5Ac) and its hydroxyl-
ed form, N-glycolylneuraminic acid (Neu5Gc), are the
o major sialic acids found in mammals and typically
rminate the antennary chains of both N-glycans and
-glycans via enzymatic addition by sialyl transferases.
eu5Gc is not expressed in humans due to the evolu-http://www.elsevier.com/locate/trac 7
http://dx.doi.org/10.1016/j.trac.2013.04.006
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verts Neu5Ac into Neu5Gc (CMP-Neu5Ac hydroxylase)
Indeed, humans possess circulating Abs against Neu5Gc
so glycans attached to protein therapeutics expressed in
cell lines capable of Neu5Gc incorporation can have th
associated immunogenic potential [51]. CE analysis o
Neu5Gc is usually done at the monosaccharide-analysi
level after labeling with a non-charged fluorophore, 2
aminoacridone [52].
8. Conclusions
This article reviewed the increasing role of CE with re
spect to N-glycosylation analysis of biotherapeutics
Glycosylation analysis is important during all the steps o
the biopharmaceutical-manufacturing process. In clon
selection, identification of all relevant glycan structures
including relative quantification of the individua
carbohydrates, is readily accomplished by CE in a high
throughput manner. CE-LIF also provides the fast turn
around time and high sensitivity that is required durin
process development to check glycosylation consistenc
and to detect the presence of possibly immunogeni
Figure 6. Automated glycan analysis flresidues. Full structural elucidation is accomplished by
exoglycosydase-array treatment followed by liquid-phase
separations or by checking critical glycosylation features
with MS. This includes full sequence analysis, purity
assessment, quantitation and identification. In formula-
tion development, possible glycosylation changes can be
readily monitored by CE. The same applies to compara-
bility studies and release analytics, which both require
detection of all sugar structures with high sensitivity and
accurate quantification under good manufacturing
practice (GMP).
To accommodate the proposal of regulatory agencies
to use orthogonal separation methods for the analysis of
biotherapeutics, CE is one of the choices, along with
8 http://www.elsevier.com/locate/trac
Please cite this article in press as: A. Guttman, Trends Anal. Chem. (20other glycoanalytical techniques (e.g., HILIC or MS). Th
orthogonality of CE-LIF and HILIC-UPLC was recentl
reported in a comparative study of analyzing fluorophor
labeled IgG glycan pools, revealing that the majo
structural sugar groups eluted/migrated in differen
positions with respect to their corresponding sugar-lad
der standards [53]. For example, while sialylated struc
tures eluted late in HILIC-UPLC, they migrated early in
CE-LIF. However, neutral glycans migrated later in CE
LIF, as their charge to hydrodynamic volume ratio wa
lower, but eluted early in HILIC-UPLC. Approximatel
the same number of glycans was identified in both
techniques.
An automated CE-based glycan-analysis flowchart i
shown in Fig. 6. This workflow can be readily applied t
the N-glycosylation analysis of the largest group of bio
pharmaceuticals, mAb therapeutics. The steps includ
purification of the IgG molecules by protein-A parti
tioning, followed by PNGase-F digestion, fluorophor
labeling, sample purification/desalting and CE separa
tion. The CE-LIF data is then analyzed and interpreted fo
structural elucidation, and also compared to publicly
art. {Adapted from [55] with permission}.482Acknowledgments
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